Can-Fite BioPharma Ltd. (TLV:CANF)
1.900
0.00 (0.00%)
Apr 1, 2025, 4:45 PM IDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 8 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
313.92K ILS
Profits / Employee
-3.47M ILS
Market Cap
59.01M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Teva Pharmaceutical Industries | 35,686 |
Danel (Adir Yeoshua) | 3,961 |
Kamada | 420 |
Bait Bakfar | 228 |
Novolog (Pharm-Up 1966) | 955 |
Ilex Medical | 223 |
BrainsWay | 134 |
SofWave Medical | 126 |
Can-Fite BioPharma News
- 12 days ago - Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market - GlobeNewsWire
- 13 days ago - Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson - GlobeNewsWire
- 4 weeks ago - Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewsWire
- 7 weeks ago - Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25 - GlobeNewsWire
- 7 weeks ago - Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025 - GlobeNewsWire
- 3 months ago - Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson - GlobeNewsWire
- 4 months ago - 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 5 months ago - Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial - GlobeNewsWire